Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imiglucerase - Sanofi

Drug Profile

Imiglucerase - Sanofi

Alternative Names: Cerecyme; Cerezyme; GZ 437843; Imiglucerase; Selezyme

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Glucosidases
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Gaucher's disease
  • Phase III Gaucher's disease type I; Gaucher's disease type III

Most Recent Events

  • 11 Apr 2018 Phase-III clinical trials in Gaucher's disease type I (In children, In adolescents, Combination therapy) in Russia (IV) (NCT03485677)
  • 11 Apr 2018 Phase-III clinical trials in Gaucher's disease type III (Combination therapy, In adolescents, In children) in Russia (IV) (NCT03485677)
  • 02 Apr 2018 Sanofi plans the phase III ELIKIDS trial for Gaucher's disease type I and type III (In children, In adolescent, Combination therapy) (IV), in March 2018 (IV) (NCT03485677)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top